secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001847903-23-000032
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors
--------------------------------------------------------------------------------

- FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.
- First LockBody candidate to enter clinic; designed to activate CD47 in tumor microenvironment avoiding systemic toxicity.
- CEO Saurabh Saha calls it an important milestone; company plans to advance multiple LockBody candidates.
- Phase 1/2a first-in-human trial initiation expected as soon as possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/0001847903-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/cnta-20230126.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer